Kodiak Q4 loss wider than expected, pipeline development in focus
The article reports that the biopharmaceutical company Kodiak experienced a wider-than-expected loss in Q4. This financial outcome puts a greater focus on the company's pipeline development as it seeks to address its financial performance. Investors will likely be watching for updates on their clinical programs and future strategic plans.
Kodiak Sciences Insider Sold Shares Worth $1,197,488, According to a Recent SEC Filing
An insider at Kodiak Sciences (NASDAQ: KOD) has sold shares valued at $1,197,488, as detailed in a recent SEC filing. The biopharmaceutical company focuses on developing treatments for retinal diseases using its Antibody Biopolymer Conjugate (ABC) Platform. Kodiak Sciences has seen recent positive news regarding its drug trials, despite an auditor raising "going concern" doubts in March.
Kodiak Sciences | 10-K: FY2025 Annual Report
This entry is a placeholder for Kodiak Sciences' FY2025 Annual Report, filed as a 10-K document. The content specifically states "Document", indicating that the report itself is expected to be contained within this entry.
Kodiak Sciences Faces Going Concern Warning As Valuation Gap Persists
Kodiak Sciences' auditor has issued a "going concern" warning even after the company reported successful Phase 3 results for Zenkuda and plans for a Biologics License Application. This puts financial stability and capital raising back into focus for the clinical-stage biopharma, which has also filed a shelf registration. Despite strong recent stock momentum and a valuation significantly below analyst expectations and Simply Wall St's fair value, the company faces pressing risks due to less than a year of cash runway, no revenue, and ongoing losses.
Lifesci Capital Forecasts Lower Earnings for Kodiak Sciences
Lifesci Capital has revised down its Q1 2026 EPS estimate for Kodiak Sciences to ($0.73) from ($0.64), impacting near-term forecasts. Despite Kodiak missing Q4 EPS estimates, the company's pipeline progress, especially with Zenkuda, has maintained a "Moderate Buy" consensus among analysts with an average price target of $35.43. The stock, heavily owned by institutional investors, trades above its moving averages, but analysts' lowered earnings projections introduce short-term uncertainty.
Q1 EPS Estimates for Kodiak Sciences Decreased by Analyst
HC Wainwright has lowered its Q1 2026 EPS estimates for Kodiak Sciences from ($0.75) to ($0.94), also trimming forecasts through 2030, but maintained a "Buy" rating and a $58 price target. The company recently reported Q4 EPS of ($1.04), missing consensus, leading to a 5.1% stock drop. Despite the analyst cuts, institutional ownership remains high with major investors increasing their stakes.
Kodiak Sciences (KOD) CFO exercises 30K options and sells 30K shares under 10b5-1 plan
Kodiak Sciences' Chief Financial Officer, John A. Borgeson, engaged in an exercise-and-sell transaction on April 2, 2026. He exercised stock options to acquire 30,000 shares at $1.04 each and simultaneously sold all 30,000 shares under a pre-arranged 10b5-1 trading plan. The sales occurred at weighted-average prices ranging from $39.14 to $41.77, leaving him with 183,316 directly held shares.
[144] Kodiak Sciences Inc. SEC Filing
This article reports on a Form 144 SEC filing by Kodiak Sciences Inc. (KOD) on April 2, 2026. The filing indicates a proposed sale of 30,000 shares of common stock with an aggregate market value of $1,284,300, acquired through the exercise of stock options. The article also provides recent news and SEC filings for Kodiak Sciences, as well as an overview of its market data.
Kodiak Sciences 2025 Financial Update
Kodiak Sciences, a precommercial biotechnology company focused on retinal diseases, reported a net loss per share of $(1.04) for Q4 2025 and $(4.32) for the full year 2025. The company ended 2025 with $209.9 million in cash and equivalents, with full-year R&D expenses at $182.4 million. An equity offering in December 2025 generated $173.0 million, expected to fund operations into 2027.
Kodiak Sciences Stock Soars Amid Positive Phase 3 Findings
Kodiak Sciences Inc. (NASDAQ: KOD) stock has risen by 11.35% due to positive Phase 3 trial results for its drug Zenkuda, which treats diabetic retinopathy. The successful trials have led to UBS and Jefferies raising their price targets for the company, indicating increased investor confidence despite high operating expenses and total liabilities. The article emphasizes that Kodiak is poised for renewed momentum driven by scientific breakthroughs and financial endorsements.
A Look At Kodiak Sciences (KOD) Valuation After Zenkuda GLOW2 Phase 3 Success And BLA Plans
Kodiak Sciences (KOD) has reported positive Phase 3 results for its drug Zenkuda, leading to a significant surge in its stock price. While a Discounted Cash Flow (DCF) model suggests the company is undervalued, its high Price-to-Book (P/B) ratio indicates strong market expectations. The article highlights the mixed sentiment and the importance of considering both potential benefits and risks given the company is still loss-making.
Kodiak Sciences (NASDAQ:KOD) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS
Kodiak Sciences (NASDAQ:KOD) reported its quarterly earnings, missing analyst expectations by $0.02 EPS with a reported ($1.04) EPS. Despite the miss, the stock rallied 13.3% to $38.12 on significant trading volume, driven by analysts raising price targets, with a consensus "Moderate Buy" rating. Kodiak is a clinical-stage biopharmaceutical company focused on retinal diseases, with its lead candidate KSI-301 under development.
BRIEF-Kodiak Sciences Q4 Net Income USD -56.736 Million
Kodiak Sciences reported a Q4 net income of USD -56.736 Million. This brief financial update was published by Reuters via Refinitiv.
Kodiak Sciences (NASDAQ:KOD) Trading Down 7.8% - Time to Sell?
Kodiak Sciences (NASDAQ:KOD) saw its stock fall 7.8% on Monday, trading at around $34.10 with lower-than-average volume. Despite this decline, Wall Street sentiment is mixed but leans positive, with UBS and HC Wainwright providing "buy" ratings and increased price targets, though Weiss Ratings issued a "sell." The company has a significant institutional ownership, and its lead ophthalmology candidate, KSI-301, is central to its focus on retinal diseases.
Kodiak Sciences: Road To $120
Kodiak Sciences (NASDAQ: KOD) saw its stock surge 62% to $37 due to strong Phase 3 GLOW2 results for Zenkuda, an experimental treatment for retinal vascular disorders, highlighting its efficacy, safety, and convenient dosing. Despite this success, the market currently undervalues Kodiak, pricing it as a clinical-stage gamble rather than a commercial entity, suggesting a potential 3x upside to over $120 per share following key milestones like the DAYBREAK readout and FDA approval. However, the company faces financial challenges, lacks a sales team, and carries inherent FDA and trial risks, which could test investor patience before a full re-rating occurs.
Kodiak Sciences (KOD) Is Up 66.3% After Zenkuda’s Phase 3 Win in Diabetic Retinopathy
Kodiak Sciences saw a 66.3% rise in stock price following positive Phase 3 results for its drug Zenkuda in treating diabetic retinopathy. The drug significantly outperformed a sham treatment and maintained a favorable safety profile, with efficacy consistent regardless of GLP-1 receptor agonist use. While this success moves Zenkuda towards BLA-ready status and offers potential for commercial viability, the company still faces financial risks due to ongoing losses and the need for future funding.
Kodiak Sciences (KOD) Is Up 66.3% After Zenkuda’s Phase 3 Win in Diabetic Retinopathy
Kodiak Sciences saw a significant stock jump after its drug Zenkuda showed positive Phase 3 results in diabetic retinopathy, outperforming a sham and maintaining a favorable safety profile. The efficacy was consistent across patient groups, including those using GLP-1 receptor agonists, making Zenkuda BLA-ready across a broader diabetic retinopathy population. Despite this clinical success, Kodiak Sciences faces ongoing financial challenges with no revenue, substantial annual losses, and funding risks, necessitating careful consideration of its investment narrative.
Kodiak Sciences (KOD) CEO exercises 300,000 stock options into common shares
Kodiak Sciences' Chairman and CEO, Victor Perlroth, exercised 300,000 stock options for common shares at an exercise price of $1.0400 per share. These options were fully vested at the time of exercise, and Perlroth now directly holds 2,395,538 shares of Common Stock. No open-market sales were reported in this transaction, indicating a conversion of derivative positions into common shares.
KOD Shares Surge Following EncKOD Shares Surge Following Encouraging Phase III Results for Eye Disorder Treatment Candidate
Kodiak Sciences (KOD) shares surged by 75% after announcing positive top-line data from its phase III GLOW2 clinical trial for Zenkuda (tarcocimab tedromer), a treatment for diabetic retinopathy. The study showed significant improvement in diabetic retinopathy severity scores for Zenkuda-treated patients compared to placebo, with favorable safety results. This success follows promising GLOW1 trial outcomes and positions Zenkuda for accelerated regulatory submission.
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate
Kodiak Sciences (KOD) shares surged 75% following positive top-line results from its Phase III GLOW2 study for Zenkuda (tarcocimab tedromer), an eye disease candidate for diabetic retinopathy. The study met its primary and secondary endpoints with statistical significance, showing significant improvement in diabetic retinopathy severity scores and reducing the risk of sight-threatening complications. This strong data positions Zenkuda for an accelerated regulatory submission, potentially offering a transformative treatment for diabetic retinopathy patients.
Kodiak Sciences’ Zenkuda Shows Strong Phase 3 GLOW2 Results
Kodiak Sciences reported strong positive results from its Phase 3 GLOW2 trial for Zenkuda, a treatment for diabetic retinopathy. The study demonstrated significant improvement over sham, reduced risks of sight-threatening complications, and favorable safety outcomes. Zenkuda is now considered BLA-ready, reinforcing Kodiak's standing in retinal therapeutics and suggesting positive implications for its broader pipeline.
Kodiak Sciences Inc. (NASDAQ:KOD) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Kodiak Sciences Inc. (NASDAQ:KOD) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month target price of $31.14. This positive sentiment follows strong topline results from its GLOW2 Phase 3 study, which showed superior efficacy for its lead product candidate, Zenkuda, leading to a significant surge in stock price and anticipated BLA filing. Despite the positive news, high institutional ownership and unusual options activity suggest potential for short-term volatility and profit-taking.
H.C. Wainwright raises Kodiak Sciences stock price target on trial data
H.C. Wainwright raised its price target for Kodiak Sciences (NASDAQ:KOD) to $58 from $38, maintaining a Buy rating, following positive Phase 3 GLOW2 trial data for tarcocimab tedromer in diabetic retinopathy. The firm also increased its probability of success for tarcocimab tedromer in several indications and noted the stock's significant surge over the past year. Earlier, the firm had also reiterated a Buy rating and raised its price target to $38 from $26 based on promising clinical trial results, including the Phase 1B APEX trial for KSI-101.
Kodiak Sciences (NASDAQ:KOD) Sets New 12-Month High - Here's What Happened
Kodiak Sciences (NASDAQ:KOD) stock surged to a new 52-week high, trading at $36.84 and closing at $36.0160, representing a 62.7% intraday gain on heavy volume. Analyst sentiment is mixed but leans positive with a "Moderate Buy" consensus and an average price target of $28.29. The clinical-stage biopharmaceutical company, focused on retinal diseases, has a market cap of $1.96 billion and significant institutional ownership, including a large stake by Vanguard Group Inc.
How Kodiak Sciences Stock Rises To $120?
Kodiak Sciences (NASDAQ: KOD) stock experienced a 75% surge due to strong Phase 3 GLOW2 data for its investigational drug Zenkuda, for retinal vascular diseases, pushing its market cap to $2.4 billion. The article suggests the stock is undervalued given its potential $1.5 billion peak sales in 2030 and could reach $120 per share with a re-rating to a conservative 5x multiple. Key milestones like the DAYBREAK readout, BLA submission, and FDA approval are critical for its valuation increase.
Kodiak Sciences (KOD) Climbs 75% on Stellar Clinical Results
Kodiak Sciences (KOD) saw its stock climb 74.77% after reporting strong results from its GLOW clinical trial for Zenkuda, a diabetic retinopathy treatment. The study showed significant improvement in diabetic retinopathy severity scores and an 85% risk reduction in sight-threatening complications, with favorable safety. The company's Chief Medical Officer highlighted the consistency and robustness of the data from both GLOW1 and GLOW2 studies.
META, KOD, U, LITE, RDDT: 5 Trending Stocks Today - Meta Platforms (NASDAQ:META)
Major U.S. indices closed lower on March 26, 2026, with the Dow Jones, S&P 500, and Nasdaq all declining. Several stocks like Meta Platforms, Kodiak Sciences, Unity Software, Lumentum Holdings, and Reddit gained investor attention due to various company-specific news and market dynamics. Meta faced a legal verdict and layoffs, Kodiak Sciences advanced a Biologics License Application, Unity Software showed strong growth in after-hours trading, Lumentum Holdings announced a new manufacturing facility to support AI data centers, and Reddit experienced a decline due to broader tech downturn and insider selling.
Kodiak Sciences (KOD) Stock Surges as Zenkuda Eye Treatment Achieves Phase 3 Success
Kodiak Sciences (KOD) stock surged following the successful completion of its GLOW2 Phase 3 clinical trial for Zenkuda (tarcocimab tedromer), an eye treatment for diabetic retinopathy. The trial demonstrated significant improvement in 62.5% of patients and an 85% reduction in sight-threatening complications, with a favorable safety profile. The company plans to expedite its Biologics License Application filing for Zenkuda based on these positive results.
Kodiak Sciences reports positive GLOW2 trial results for Zenkuda
Kodiak Sciences Inc. announced positive results from its GLOW2 Phase 3 study of Zenkuda (tarcocimab tedromer) for diabetic retinopathy, meeting its primary endpoint. The drug significantly improved diabetic retinopathy severity scores and reduced the risk of sight-threatening complications. Based on these results, Kodiak Sciences plans to accelerate its Biologics License Application submission for Zenkuda.
Kodiak Sciences Up Over 74%, on Pace for Record Percent Increase -- Data Talk
Kodiak Sciences (KOD) stock surged over 74% in morning trading, putting it on track for its largest ever percentage increase. This significant rise follows the company's release of positive data from its BEACON study of tarcocimab in diabetic macular edema and its GLOW study of tarcocimab in retinal vein occlusion.
Kodiak Sciences shares soar after eye drug succeeds in late-stage study
Kodiak Sciences' shares surged by 68.6% after its experimental drug, Zenkuda, achieved its primary goal in a late-stage study for diabetes-related eye damage. The drug showed significant improvement in retinopathy severity and reduced the risk of sight-threatening complications, leading to plans for accelerated FDA approval submission. This success also boosts confidence in Kodiak's broader drug-development platform and de-risks future studies.
Kodiak Sciences (KOD) Stock Jumps After Eye Drug Passes Major Trial
Kodiak Sciences' stock surged after its GLOW2 Phase 3 study of Zenkuda for diabetic retinopathy met its primary endpoint, showing significant improvement in patients and an 85% reduction in sight-threatening complications. The drug demonstrated a good safety profile with no reported intraocular inflammation, leading Kodiak to accelerate its Biologics License Application submission. Analysts like H.C. Wainwright and UBS maintain "Buy" ratings on KOD.
Kodiak Sciences Stock Hits 52-Week High - Here's Why
Kodiak Sciences (NASDAQ:KOD) stock surged to a 52-week high after announcing positive results from its GLOW2 Phase 3 study for Zenkuda (tarcocimab tedromer) in treating diabetic retinopathy. Zenkuda demonstrated statistically significant efficacy, showing substantial improvement in Diabetic Retinopathy Severity Scale scores and a significant reduction in sight-threatening complications. The company is advancing plans for a Biologics License Application (BLA) submission for the treatment.
Kodiak Sciences shares soar after eye drug succeeds in late-stage study
Kodiak Sciences' shares significantly increased following the successful outcome of a late-stage study for its eye medication. This positive development was reported by Reuters via Refinitiv. The article is a brief news update confirming the drug's success and its immediate impact on the company's stock.
Kodiak Sciences (KOD) Surges on Positive Phase 3 Trial Results for Eye Therapy
Kodiak Sciences (KOD) shares surged 33% due to positive Phase 3 trial results for Zenkuda, a diabetic retinopathy treatment, showing significant improvement in 63% of patients. The company plans to expedite its Biologics License Application submission. Despite strong trial results and analyst "moderate buy" sentiment, Kodiak Sciences faces financial challenges with zero revenue, negative EPS, significant leverage, and a "Distressed" financial health grade.
Kodiak Sciences' Zenkuda Therapy Achieves Key Milestones in Phase 3 Trial
Kodiak Sciences announced significant success in its Phase 3 trial for Zenkuda, an eye disorder therapy, with 63% of diabetic retinopathy patients showing marked improvement and a strong safety profile. Wall Street analysts have upgraded their ratings and price targets for Kodiak, anticipating commercial success and an accelerated Biologics License Application submission. The positive results and improved formulation of tarcocimab are expected to enhance its market acceptance and future revenue potential across various retinal vascular diseases.
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
Kodiak Sciences announced positive topline results from its GLOW2 Phase 3 study for Zenkuda™ (tarcocimab tedromer) in diabetic retinopathy, demonstrating significant superiority over sham in improving disease severity and reducing sight-threatening complications. The study showed strong efficacy regardless of concomitant GLP-1 receptor agonist use and a favorable safety profile. These results support an accelerated Biologics License Application (BLA) submission for Zenkuda across multiple indications.
Kodiak Sciences reports positive GLOW2 trial results for Zenkuda By Investing.com
Kodiak Sciences Inc. announced positive results from its GLOW2 Phase 3 study of Zenkuda (tarcocimab tedromer) for treating diabetic retinopathy, leading to a significant increase in its stock price. The study met its primary endpoint, showing substantial improvement in diabetic retinopathy severity and an 85% risk reduction in sight-threatening complications. The company plans to expedite its Biologics License Application submission based on these findings, although InvestingPro analysis suggests the stock is currently overvalued.
Kodiak posts trial win for diabetic retinopathy drug (KOD)
Kodiak Sciences' stock surged approximately 33% in premarket trading after announcing positive Phase 3 trial results for its diabetic retinopathy drug, Zenkuda. The trial, observing patients over 48 weeks, met its primary endpoints. Diabetic retinopathy is a serious eye complication associated with diabetes.
Kodiak Sciences Inc stock faces analyst scrutiny amid biotech pipeline delays and hold consensus
Kodiak Sciences Inc. is under analyst scrutiny due to mixed views on its pipeline progress for retinal disease therapies, particularly tarcocimab tedromer for wet AMD. Analysts have issued a consensus 'Hold' rating, citing potential from successful trial outcomes balanced against execution risks and repeated delays in data readouts. US investors are closely monitoring clinical developments and the company's financial position, which supports operations through key trial readouts into late 2026.
Kodiak Sciences Inc stock faces analyst scrutiny amid biotech pipeline delays and hold consensus
Kodiak Sciences Inc (KOD) is facing analyst scrutiny due to pipeline delays in its lead asset, tarcocimab tedromer, for wet AMD, resulting in a consensus "Hold" rating. Investors are closely watching for Phase 3 trial readouts, which have been repeatedly delayed, pushing key catalysts into 2026. While the company maintains a cash position to support operations through late 2026, concerns remain regarding execution risks, competition, and potential capital raises for market launch.
Kodiak Sciences (KOD) CEO awarded 175k performance-based options at $25
Kodiak Sciences Inc. (KOD) reported that its CEO, Victor Perlroth, was granted 175,000 performance-based stock options with an exercise price of $25.00. The vesting of these options is tied to the company's 30-day average stock price as of June 30, 2027, with full vesting occurring if the price exceeds $35.00, subject to his continued service. This grant is a compensation package rather than an open-market transaction.
Kodiak Sciences (KOD) to Release Quarterly Earnings on Thursday
Kodiak Sciences (KOD) is scheduled to release its Q4 2025 earnings before market open on Thursday, March 26th, with analysts expecting a loss of ($1.02) per share. The company currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $28.29. Institutional investors own a significant portion of Kodiak Sciences, with notable recent investments from firms like Braidwell, RTW, Janus Henderson, Goldman Sachs, and State Street.
Boone Capital Management Invests $11.72M in Kodiak Sciences
Boone Capital Management LLC has invested $11.72 million in Kodiak Sciences Inc. (NASDAQ:KOD), acquiring 715,877 shares and becoming the 12th largest shareholder. This significant investment signals confidence in Kodiak Sciences' lead candidate KSI-301, a potential treatment for retinal diseases like wet AMD and DME. The capital injection is expected to accelerate Kodiak's clinical development efforts for innovative eye therapies.
Boone Capital Management LLC Invests $11.72 Million in Kodiak Sciences Inc. $KOD
Boone Capital Management LLC has made a significant investment in Kodiak Sciences Inc. (NASDAQ:KOD), acquiring 715,877 shares valued at $11.72 million. This represents a substantial portion of Boone's portfolio and 1.35% of Kodiak's shares. Insider activity also shows Bros. Advisors LP Baker increasing their stake with a $60 million purchase, contributing to insiders owning nearly 46% of the company's stock.
KOD Earnings History & Surprises | EPS & Revenue Results | KODIAK SCIENCES INC (NASDAQ:KOD)
This article provides a detailed historical overview of KODIAK SCIENCES INC (KOD) quarterly earnings, including EPS and revenue actuals, analyst estimates, and surprise percentages. It highlights that KOD last reported earnings on November 13, 2025, missing both EPS and revenue estimates, and has beaten EPS estimates in 2 out of the last 4 quarters, with an average miss of 5.5%. The next earnings report for Q4 2025 is scheduled for March 26, 2026.
Bruce & Co. Inc. Sells 43,692 Shares of Kodiak Sciences Inc. $KOD
Bruce & Co. Inc. reduced its stake in Kodiak Sciences Inc. by 13.5% in the third quarter, selling 43,692 shares and now holding 279,308 shares valued at $4.57 million. Despite Bruce & Co.'s reduction, company insiders, particularly Director Bros. Advisors Lp Baker, increased their holdings significantly. The company, a clinical-stage biopharmaceutical firm, currently has a "Moderate Buy" rating from analysts with an average price target of $28.29.
Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Swings
Kodiak Sciences (KOD) has experienced recent share price swings, including a 3.5% gain, benefiting from rebuilding investor expectations after prior losses. While a Discounted Cash Flow (DCF) model suggests the stock is heavily undervalued with a fair value of $80.15 against a current price of $25.72, its Price-to-Book (P/B) ratio indicates it is very expensive compared to peers. The article highlights the sensitivity of DCF for clinical-stage biotechs and suggests investors consider both long-term potential and current balance sheet multiples.
KOD SEC Filings - Kodiak Sciences Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Kodiak Sciences Inc. (KOD) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading activities. It highlights the company's focus on developing biologic therapeutics for retinal vascular diseases, detailing how filings reflect program progress and funding, such as public offerings and clinical trial updates. Investors can use this platform and its AI tools to analyze regulatory documents for key financial disclosures and clinical milestones.
TD Asset Management Inc Acquires New Stake in Kodiak Sciences Inc. $KOD
TD Asset Management Inc. has acquired a new stake in Kodiak Sciences Inc. (NASDAQ: KOD), purchasing 60,600 shares valued at approximately $992,000 during the third quarter. Other institutional investors like Adage Capital Partners and Vanguard Group have also adjusted their holdings. The report highlights significant insider buying, with Director Bros. Advisors Lp Baker acquiring over 2.6 million shares.
